FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely nephrology, and may be used for administering alendronate as an agent for low-turnover metabolic bone disease in the patients suffering chronic renal insufficiency (CRI).
EFFECT: invention provides preventing developing incurable adynamic bone disease and transforming the low-turnover metabolic bone disease into the high-turnover metabolic bone disease thereby reducing the risks of fractures and a cardiovascular pathology, increasing the survival rate in the CRI patients.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR LOW-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2485957C1 |
METHOD OF TREATING PATIENTS WITH ATROPHY OF ALVEOLAR PART OR DENTAL PROCESS IN OSTEOPENIC SYNDROME | 2008 |
|
RU2377012C1 |
METHOD OF TREATING OSTEOPENIC SYNDROME IN POSTMENOPAUSAL OBESITY WOMEN | 2017 |
|
RU2698269C2 |
DIAGNOSTIC TECHNIQUE FOR CHRONIC AGGRESSIVE GENERALISED PERIODONTITIS | 2008 |
|
RU2415426C2 |
METHOD OF TREATMENT OF OSTEOPOROSIS IN WOMEN IN POSTMENOPAUSE AGAINST THE BACKGROUND OF OBESITY | 2017 |
|
RU2657789C1 |
METHOD FOR TREATMENT OF PATIENTS WITH STAGE V CHRONIC KIDNEY DISEASE AT DIALYSIS STAGE | 2020 |
|
RU2753127C1 |
METHOD OF POSTMENOPAUSAL OSTEOPOROSIS THERAPY | 2009 |
|
RU2423982C2 |
METHOD FOR NON-INVASIVE DIFFERENTIAL DIAGNOSIS OF PERIOCYTHOUS GREASES | 2021 |
|
RU2755931C1 |
METHOD OF TREATING CHRONIC GENERALISED PERIODONTITIS WITH AGGRESSIVE CLINICAL COURSE | 2008 |
|
RU2383348C1 |
METHOD FOR CORRECTING BONE TISSUE STATUS AND PREVENTING FRACTURES IN CARDIOVASCULAR PATIENTS | 2013 |
|
RU2552300C2 |
Authors
Dates
2013-09-10—Published
2012-03-16—Filed